HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain
Funds optimizing an existing non-addictive pain drug or biologic candidate through IND filing and into a first human trial.
Pain treatment has leaned on addictive drugs for a long time because the safer alternatives keep stalling before they reach people. This notice funds pushing a specific kind of candidate past that stall point.
It is part of the HEAL Initiative, and it only accepts applicants who already have a promising small molecule or biologic lead for pain — the notice asks for a strong biological rationale f…
Preclinical optimisation and IND-enabling development of an existing non-addictive small molecule or biologic candidate for pain, including pharmacodynamic and target-engagement biomarker development, IND submission and a first Phase I clinical trial, as a milestone-driven phased cooperative agreement.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up